Clinical Trials
23 trialsNCT03568058 2026-03-24
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
University of California, San Diego
Phase 1 Completed
NCT01351103 2025-06-13
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis
Phase 1 Completed
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed
NCT04672434 2024-12-09
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT03523819 2024-09-19
A Study of CS1002 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT04641871 2024-06-26
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT02828098 2024-01-29
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Highlight Therapeutics
Phase 1 Completed
NCT02658981 2023-10-06
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03311412 2023-05-30
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
Phase 1 Completed
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT03111992 2022-02-09
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT02947165 2022-01-31
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Completed
NCT02403193 2022-01-12
AdenONCO
Palobiofarma SL
Phase 1 Completed
NCT02112032 2021-05-05
Treatment of Advanced Melanoma With MK-3475 and Peginterferon
University of Pittsburgh
Phase 1 Completed
NCT02740270 2021-02-21
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
Novartis
Phase 1 Completed
NCT02988440 2020-12-19
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Novartis
Phase 1 Completed
NCT03081494 2020-12-11
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Novartis
Phase 1 Completed
NCT02678260 2018-06-08
Phase I Study of PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Completed